|
Why Canada hasn’t been getting the new antibiotics we need to fight drug-resistant ‘superbugs’
Wednesday, March 2nd, 2022
… due to the cost of developing these drugs and their susceptibility to eventual resistance, many pharmaceutical companies have abandoned antibiotic development… newer antibiotics are used only as a last resort, reducing the volume of sales and return on investment for companies that are still willing to bear the costs of development… [and] manufacturers still producing antibiotics tend to shy away from the Canadian market due to Canada’s small population, financial barriers in our publicly funded system and burdensome regulatory processes.
Tags: Health, pharmaceutical, privatization, standard of living
Posted in Health Delivery System | No Comments »
Recent Comments